Biography
Dr. Fenniri was educated at the Université de Strasbourg, France, receiving his undergraduate degree in chemistry and biochemistry, and his M.Sc./Ph.D. degrees in supramolecular science and engineering under Nobel Laureate Professor Jean-Marie Lehn. He then joined the Scripps Research Institute in California, USA, where he carried out his postdoctoral training under the supervision of Professor Richard A. Lerner. In 1997 he moved to Purdue University, where he initiated his independent academic career, and established the Purdue Laboratory for Chemical Nanotechnology. In 2003, He joined National Institute for Nanotechnology (NINT) as a founding member and the University of Alberta where he led the Supramolecular Nanoscale Assembly program. Since 2013, Dr. Fenniri has been Professor of Chemical and Biomedical Engineering at Northeastern University, Boston, MA, USA. Dr. Fenniri has achieved international recognition as a leader in the areas of self-assembly, supramolecular chemistry, nanomedicine, and materials sciences. His group works at the forefront of basic and applied nanosciences, in collaboration with various academic institutions, federal laboratories, and with the private sector. Dr. Fenniri’s contributions appeared in over 220 publications, 20 patents and patent applications, and over 450 contributed national and international conference papers. Dr. Fenniri has also presented his work in over 170 invited distinguished lectures, colloquia and seminars around the globe. Dr. Fenniri is the recipient of several academic and professional honours and awards, including the Xerox UAC Award, the 3M Faculty Award, the Showalter Trust Fund Award, the Trask Trust Fund Technology Innovation Award, the Cottrell Teacher Scholar Award, and the US National Science Foundation Career Award. Dr. Fenniri is Member of the Editorial Board of several scientific journals and serves on several national and international scientific boards, panels, and committees.
Research Interest
Nanotechnology for biomedical applications, nanoscale materials for drug delivery, and cell therapeutics and regenerative medicine.
Biography
Esmaiel Jabbari completed his PhD at Purdue University and postdoctoral studies at Monsanto, Rice University, and Mayo Clinic. He is Full Professor of Chemical and Biomedical Engineering and Director of Biomimetic Materials and Tissue Engineering Laboratory at University of South Carolina. He is internationally known for his work on synthesis and processing of cell-responsive polymers and hydrogels for applications in tissue engineering and regenerative medicine. He received the Berton Rahn Award from the AO Foundation in 2012 and the Stephen Milam Award from the Oral and Maxillofacial Surgery Foundation in 2008. He was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE) in 2013. He has published >230 books, book chapters, peer-reviewed journal articles, and conference proceedings, and presented >260 seminars at national and international conferences on biomaterials, tissue engineering, and drug delivery. He has mentored >130 visiting scholars, post-doctoral researchers, doctoral students, and undergraduate students. He is a member of numerous scientific organizations including BMES, SFB, TERMIS, MRS, EMBS, ACS, AIChE, and AACR.
Research Interest
Bioinspired materials, Skeletal tissue engineering, Multiâ€scale composite materials, Self-assembled nanogels for growth factor delivery, Drug targeting to cancer stem cells, Stem cell encapsulation and delivery, Model gels to control cell microenvironment
Biography
Julie Allickson, Director of the Regenerative Medicine Clinical Center at Wake Forest Institute for Regenerative Medicine focuses on the translation of regenerative medicine products including cell therapy, tissue engineering, biomaterials and devices. This process begins at Proof-of-Concept where early discussion with regulators and clinicians are critical in moving the technology from the bench to the bedside. The Translational Team includes Quality Assurance, Quality Control, Regulatory Affairs, Process Development and the GMP-complaint Manufacturing Facility. Prior to joining the institute, she was an Executive Officer of the company and Vice President of Laboratory Operations and R & D at Cryo-Cell International, Inc. As Vice President of the Laboratory Dr. Allickson was responsible for all technical aspects of Laboratory Operations along with Research and Development activities associated with adult stem cells, and the commercialization of a unique stem cell harvested from menstrual blood. Prior to this position, Dr. Allickson worked for the University Of Miami School Of Medicine, Diabetes Research Institute as the Laboratory Director of the cGMP Hematopoietic Cell Processing Facility. She was responsible for the design and implementation of the State Licensed Clinical Flow Cytometry Laboratory. Dr. Allickson was the lead in Regulatory Affairs for the processing laboratory of Islet and Hematopoietic Cell products which included oversight of all Investigational New Drugs (IND) and external regulations. Prior to working for the University of Miami she worked for the American Red Cross managing the Hematopoietic Cell Processing and Platelet Serology Laboratory. During her tenure at the American Red Cross she served as a member of the National Stem Cell Task Force and participated in the preparation of national protocols developed for Hematopoietic Cell Processing Laboratories. Dr. Allickson was part of the team to perform the very first Bone Marrow Transplant at the University of Miami in 1990. Dr. Allickson has 25 years of experience in Cellular Therapy, Cellular Processing and Regenerative Medicine. She has a Doctorate in Health Sciences along with a Master’s Degree in Medical Laboratory Sciences. She is one of the founding members of the International Society of Cellular Therapy in 1992, has been a member of the American Association of Blood Banks (AABB) for 25 years along with other organizations such as TERMIS. She has presented at meetings related to cellular therapy, tissue engineering and biomaterial clinical translation. Dr. Allickson is on the AABB Standards Committee for Cell Therapy Product Services , Technical Advisory Board for Tissue Engineered Products under ICCBBA, Cord Blood Association on Market Expansion and Vice Chair of the Quality Committee and the ISCT Commercialization Committee.
Research Interest
Cellular Therapy, Cellular Processing and Regenerative Medicine,tissue engineering and biomaterial clinical translation.